Singapore, Jan. 13 -- US-based Curi Bio, the leader in delivering human-relevant functional data for drug discovery and development, has announced the formal establishment of Curi Bio Co., Ltd., a wholly-owned subsidiary, following the full acquisition of Quvit Bio of South Korea.

The new subsidiary will serve as Curi Bio's commercial and operational hub in the Asia-Pacific (APAC) market, significantly expanding its direct presence and scientific capabilities to serve its growing customer base.

"Curi Bio Co., Ltd. represents a day-1 ready sales, R&D, and operational hub, allowing us to directly serve the APAC market. We can now offer localised technical and sales support for our existing customer base across South Korea, Japan, and Chin...